Navigation Links
GeoVax Labs, Inc. Third Quarter Financial Results and Operational Update
Date:11/15/2007

ng Board recommended that the trial be

stopped because it was not reaching its efficacy endpoints. GeoVax

responded to the discontinuance of Merck's trial by pointing out

significant differences between the GeoVax vaccine technology and the

technology used in the Merck trial.

GeoVax AIDS vaccines advancing in human trials represent a

significantly different vaccine approach, vaccine composition and

results to date than the Merck vaccine.

* Prototypes for the GeoVax vaccines were selected from a series of

trials in non-human primates for their ability to protect against

the development of AIDS when vaccinated individuals were

administered an AIDS causing virus. At each major step along the

development pathway, GeoVax vaccines providing the best protection

against AIDS were moved forward.

* GeoVax AIDS vaccines demonstrated excellent protective results in

non-human primate models, much better protective results than

reported for Merck's vaccine in similar models. GeoVax AIDS

vaccines protected 22/23 non-human primates for over 3 1/2 years

and 5/6 non-vaccinated controls died of AIDS post-AIDS virus

infection.

* GeoVax AIDS vaccines are designed to elicit protective antibodies

(Ab) as well as protective T cells (white blood cells) against the

AIDS virus. The Merck vaccine stimulates only T cells for providing

protection and does not include the Env protein of HIV which is the

target for protective antibody (Ab).

* Protective Ab has been difficult to elicit with HIV/AIDS vaccines.

GeoVax has approached this challenge by vaccinating with the

natural form of Env (HIV envelope antigens) under conditions that

elicit tightly binding Ab. GeoVax studie
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. GeoVax Successful HIV/AIDS Vaccine Trial Data Presented at AIDS Vaccine 2007 Conference
2. GeoVax Labs, Inc. Comments on Discontinuance of Mercks HIV Vaccine Trial
3. Excellent Results Received from GeoVaxs Full-Dose HIV/AIDS Vaccine Trial
4. Biopure Announces 2007 Third Quarter Financial Results
5. Gen-Probe Announces Webcast of Third Quarter 2007 Earnings Conference Call
6. The Quigley Corporation Reports Third Quarter Results, Increases Investment in Pharmaceutical R&D for Diabetic Neuropathy
7. Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
8. QIAGEN N.V. (Nasdaq: QGEN) Invites You to Join Its Third Quarter 2007 Earnings Conference Call on the Web
9. Pharmacopeia Announces Third Quarter 2007 Financial Results
10. Emisphere Technologies, Inc. Announces 2007 Third Quarter Financial Results
11. PharmAthene to Webcast its Third Quarter Conference Call on November 13, 2007 at 4:30 P.M. Eastern Time
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... -- NxStage Medical, Inc. (Nasdaq: NXTM ), a leading ... H. Burbank , Chief Executive Officer, and Mathew Towse ... Annual Canaccord Genuity Growth Conference being held at the ... August 13 th at 4:30 p.m. ET.  A webcast ... .  About NxStage Medical NxStage ...
(Date:8/1/2014)... -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ... financial results for the second quarter ended June ... to see encouraging advancements in the US commercialization ... estimated total prescriptions and estimated total per week ... Arena,s President and Chief Executive Officer. "Other recent ...
(Date:7/31/2014)... Surgical Company (NASDAQ: STAA ) a leading ... systems for the eye today reported revenue for the ... a 10% increase over $18.2 million reported for the ... revenues grew 11% during the second quarter of 2014 ... of foreign currency exchange reduced sales by $0.1 million ...
Breaking Medicine Technology:NxStage to Present at the 34th Annual Canaccord Genuity Growth Conference 2Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 2Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 3Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 4Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 5Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 6Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 7Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 8Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 9Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 10Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 11STAAR Surgical Reports 10% Second Quarter Revenue Growth 2STAAR Surgical Reports 10% Second Quarter Revenue Growth 3STAAR Surgical Reports 10% Second Quarter Revenue Growth 4STAAR Surgical Reports 10% Second Quarter Revenue Growth 5STAAR Surgical Reports 10% Second Quarter Revenue Growth 6STAAR Surgical Reports 10% Second Quarter Revenue Growth 7STAAR Surgical Reports 10% Second Quarter Revenue Growth 8STAAR Surgical Reports 10% Second Quarter Revenue Growth 9STAAR Surgical Reports 10% Second Quarter Revenue Growth 10STAAR Surgical Reports 10% Second Quarter Revenue Growth 11STAAR Surgical Reports 10% Second Quarter Revenue Growth 12STAAR Surgical Reports 10% Second Quarter Revenue Growth 13STAAR Surgical Reports 10% Second Quarter Revenue Growth 14STAAR Surgical Reports 10% Second Quarter Revenue Growth 15STAAR Surgical Reports 10% Second Quarter Revenue Growth 16STAAR Surgical Reports 10% Second Quarter Revenue Growth 17STAAR Surgical Reports 10% Second Quarter Revenue Growth 18STAAR Surgical Reports 10% Second Quarter Revenue Growth 19STAAR Surgical Reports 10% Second Quarter Revenue Growth 20STAAR Surgical Reports 10% Second Quarter Revenue Growth 21STAAR Surgical Reports 10% Second Quarter Revenue Growth 22STAAR Surgical Reports 10% Second Quarter Revenue Growth 23STAAR Surgical Reports 10% Second Quarter Revenue Growth 24STAAR Surgical Reports 10% Second Quarter Revenue Growth 25
... 30 Aethlon Medical, Inc. (OTC Bulletin Board: ... devices to address infectious disease and cancer, announced today ... in the establishment of federal partnerships that advance biodefense, ... Hemopurifier®. The Aethlon Hemopurifier® is the first medical device ...
... 30 Covance Inc. (NYSE: CVD ) ... (EURONEXT: SAN and NYSE: SNY ) for ... ten years, Covance expects to provide drug development services ... billion to $2.2 billion.  Sanofi-aventis will sell their Porcheville, ...
Cached Medicine Technology:Aethlon Medical Engages Fabiani & Company to Advance U.S. Government Partnerships 2Aethlon Medical Engages Fabiani & Company to Advance U.S. Government Partnerships 3Aethlon Medical Engages Fabiani & Company to Advance U.S. Government Partnerships 4Aethlon Medical Engages Fabiani & Company to Advance U.S. Government Partnerships 5Covance and Sanofi-Aventis Sign Definitive Agreements for 10-Year Strategic R&D Alliance 2Covance and Sanofi-Aventis Sign Definitive Agreements for 10-Year Strategic R&D Alliance 3
(Date:8/1/2014)... York (PRWEB) August 01, 2014 ... the wake of the 2012 Rejuvenate and ABG ... forward in New Jersey’s Bergen County Superior Court, ... in the proceeding, the Court has issued ... governing any and all hard copy and electronic ...
(Date:8/1/2014)... 2014 Summer is here, and with it ... the summer, and they can be a pain for dogs. ... help all their customers get rid of ticks and prevent ... eggs in the summer, which is why they are so ... grass and woodland areas and carry a number of diseases, ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 The ... (D-CA), Gregg Harper (R-MS), and Peter Welch (D-VT), ... the Medicare Telehealth Parity Act of 2014, which ... support this effort to improve healthcare access and ... executive officer of ATA. "These cost-saving provisions are ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 The ... others such as Zinc Oxide, Titanium Dioxide, and ... Building & Construction, Food & Beverages, Textiles, and ... ROW) - Global Trends and Forecasts to 2018" ... market drivers, opportunities, and trends in the diverse ...
(Date:8/1/2014)... August 01, 2014 The North America ... security solutions market in North America with analysis and ... from around $3.53 billion in 2014 to $4.77 billion ... to 2019. , Browse through the TOC of the ... idea of the in-depth analysis provided. It also provides ...
Breaking Medicine News(10 mins):Health News:Stryker Hip Lawsuit News: New Order Issued in New Jersey Stryker Hip Recall Litigation, Bernstein Liebhard LLP Reports 2Health News:Stryker Hip Lawsuit News: New Order Issued in New Jersey Stryker Hip Recall Litigation, Bernstein Liebhard LLP Reports 3Health News:Tis the Season for Tick Prevention 2Health News:ATA Applauds Bill on Medicare Telemedicine Improvements 2Health News:Antimicrobial Coatings Market Projected to Reach $2.9 Billion by 2018 – Report by MarketsandMarkets 2Health News:Antimicrobial Coatings Market Projected to Reach $2.9 Billion by 2018 – Report by MarketsandMarkets 3Health News:Antimicrobial Coatings Market Projected to Reach $2.9 Billion by 2018 – Report by MarketsandMarkets 4Health News:North America End-Point Security Market is Expected to Reach $4 billion in 2019 - New Report by MicroMarket Monitor 2Health News:North America End-Point Security Market is Expected to Reach $4 billion in 2019 - New Report by MicroMarket Monitor 3Health News:North America End-Point Security Market is Expected to Reach $4 billion in 2019 - New Report by MicroMarket Monitor 4
... With the economic crisis facing this nation, hospitals are ... many companies offering various services and ideas on how ... efforts on the front-end registration process, dealing with eligibility ... All these procedures are important and are a good ...
... Corp. (Nasdaq: WBMD ), the leading provider ... announced a long-term strategic relationship with Boots UK Limited, ... United Kingdom, to jointly develop a consumer health and ... offering will leverage WebMD,s online consumer health assets and ...
... consumers are turning to webLAB to save time and money by ... today announced that consumers can now store, track and trend their ... an open, Web-based platform designed to empower consumers by putting them ... ...
... maintaining recommendation in support of LCA,s current board, urges ... (Nasdaq: LCAV ) announces that RiskMetrics Group,s ... its recommendation that LCA-Vision stockholders vote to retain ... proposals, including the removal of the current Directors and ...
... /PRNewswire-FirstCall/ - Transition Therapeutics Inc. ("Transition" or the ... that the first patient has been dosed in ... combination with a proprietary Lilly GLP-1 analogue, in ... a randomized, double-blind, placebo-controlled study in approximately 140 ...
... Medical images are increasingly becoming digitised. However, ... poses an immense challenge in terms of ... that image archive storage solution providers, picture ... image modality manufacturers become aware of the ...
Cached Medicine News:Health News:OCExaminer Gives More Cash to Hospitals 2Health News:OCExaminer Gives More Cash to Hospitals 3Health News:WebMD Announces Strategic Relationship with Boots UK to Launch New Consumer Health Portal in UK 2Health News:WebMD Announces Strategic Relationship with Boots UK to Launch New Consumer Health Portal in UK 3Health News:PWN Announces That Consumers Can Now Store webLAB Test Results In Their Microsoft HealthVault Account 2Health News:PWN Announces That Consumers Can Now Store webLAB Test Results In Their Microsoft HealthVault Account 3Health News:RiskMetrics Affirms Recommendation that Stockholders Support LCA-Vision Board of Directors and Reject All Proposals by Dissident Joffe Group 2Health News:RiskMetrics Affirms Recommendation that Stockholders Support LCA-Vision Board of Directors and Reject All Proposals by Dissident Joffe Group 3Health News:Transition Therapeutics Announces Initiation of a Phase Ib Clinical Study of TT-223 in combination with a GLP-1 analogue in Patients with Type 2 Diabetes 2Health News:Europe Poised for Exponential Growth in the Digitised Medical Imaging Storage Space, Reveals Frost & Sullivan 2Health News:Europe Poised for Exponential Growth in the Digitised Medical Imaging Storage Space, Reveals Frost & Sullivan 3Health News:Europe Poised for Exponential Growth in the Digitised Medical Imaging Storage Space, Reveals Frost & Sullivan 4
... with concave seats and large backrests with ... backrests, armrests, and casters and glides. • ... in a variety of environments including: industry, ... care and office. • With cast aluminum ...
... concave seats and large backrests with ... seats, backrests, armrests, and casters and ... for top performance in a variety ... clean room, static control, health care ...
... chairs with concave seats and large backrests ... seats, backrests, armrests, and casters and glides. ... performance in a variety of environments including: ... health care and office. • With tubular ...
... chairs with concave seats and large ... options like seats, backrests, armrests, and ... BE Series for top performance in ... education, laboratory, clean room, static control, ...
Medicine Products: